GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)

GARDASIL Reexamination Study (V501-059)

NCT01062074 ·Status: COMPLETED

Post-marketing Surveillance of GSK Biologicals' Cervarix™ When Administered to Healthy Females in Sri Lanka

NCT01551537 ·Status: WITHDRAWN

Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)

NCT02653118 ·Status: ACTIVE_NOT_RECRUITING

Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

NCT00543543 ·Status: COMPLETED ·Phase: PHASE3

Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)

NCT01078220 ·Status: COMPLETED

Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)

NCT00157950 ·Status: COMPLETED ·Phase: PHASE3

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

NCT00520598 ·Status: COMPLETED ·Phase: PHASE2

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

NCT00092495 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

NCT03158220 ·Status: COMPLETED ·Phase: PHASE3

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

NCT00496626 ·Status: COMPLETED ·Phase: PHASE3

An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)

NCT00635830 ·Status: COMPLETED ·Phase: PHASE1

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

NCT01047345 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

NCT01304498 ·Status: COMPLETED ·Phase: PHASE3

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

NCT05372016 ·Status: COMPLETED ·Phase: PHASE3

Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)

NCT00365378 ·Status: COMPLETED ·Phase: PHASE2

V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)

NCT05450705 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

NCT03493542 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

NCT00551187 ·Status: COMPLETED ·Phase: PHASE2

A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)

NCT02114385 ·Status: COMPLETED ·Phase: PHASE3

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

NCT03546842 ·Status: COMPLETED ·Phase: PHASE3

Effectiveness Study of Gardasil on Condyloma

NCT01553994 ·Status: COMPLETED

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

NCT01462357 ·Status: COMPLETED ·Phase: PHASE3

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

NCT00423046 ·Status: COMPLETED ·Phase: PHASE3

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

NCT05580341 ·Status: UNKNOWN ·Phase: PHASE3

A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.

NCT02733068 ·Status: COMPLETED ·Phase: PHASE3